Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, will invest in expanding drug product manufacturing capabilities in Switzerland with an additional aseptic flexible filling line for clinical supply of drug product in Stein (CH).
 
The new line will support liquid and lyophilized vial filling and processing, cartridges and pre-filled syringes. The new filling line will allow Lonza to process various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and other gene therapy products. The filling line will use state-of-the-art robotic technology and implement innovative freeze-drying technology with a sustainable air-cooling system. The installation is expected to be completed in 2023 and will create more than 70 new jobs at the Stein site.
 
The investment will also include a footprint extension of its Drug Product Services (DPS) for parenteral dosage forms in Basel (CH), that will further support the pharmaceutical development for early and late clinical stages and increase the process development and characterization capabilities. The expansion will strengthen the integrated drug substance and drug product offering across multiple modalities. The new DPS facilities in Basel are expected to be operational in 2024.
 
Jean-Christophe Hyvert, President, Biologics and Cell and Gene, Lonza, commented, “The drug product capability expansions in Switzerland provide our customers with access to a flexible, integrated offering comprising the development, testing and manufacturing services for mammalian, microbial, bioconjugate products, cell and gene therapies, and small molecules. Enhancing our global drug product capacity underlines Lonza’s continuing commitment to providing our customers with an end-to-end solution across various modalities and scales.”